Laurus Labs Limited Bombay S.E.

Equities

LAURUSLABS

INE947Q01028

Pharmaceuticals

Delayed Bombay S.E. 05:54:02 2024-04-26 am EDT 5-day change 1st Jan Change
437 INR +2.75% Intraday chart for Laurus Labs Limited +2.53% +1.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024
Laurus Labs' Consolidated Profit Falls in Fiscal Q4 MT
Laurus Labs Limited Approves Second Interim Dividend for the Financial Year 2023-2024, Payable on or After May 17, 2024 CI
Laurus Labs Limited Approves Board Changes CI
Laurus Labs Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Laurus Labs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Laurus Labs Board to Consider Second Interim Dividend for Fiscal Year 2024 MT
Laurus Labs Incorporates New JV Company with Slovenia-Based Pharmaceutical Company MT
Laurus Labs, Slovenia's Krka to Form JV; Laurus Shares Fall 6% MT
Laurus Labs Limited Reaches to Agreement with Krka to Establish Joint Venture Company in Hyderabad, India Namely Krka Pharma Pvt. Ltd CI
Jefferies Adjusts Laurus Labs’ Price Target to INR250 From INR290, Keeps at Underperform MT
Laurus Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Laurus Labs Limited, Q3 2024 Earnings Call, Jan 24, 2024
INDIA STOCKS-IT drives losses in Indian shares ahead of Fed policy outcome RE
Indian shares set to open higher; focus turns to Fed policy RE
Laurus Labs Completes Acquisition of Additional Stake in Laurus Bio MT
Laurus Labs Limited completed the acquisition of additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders. CI
Jefferies Adjusts Laurus Labs’ Price Target to INR260 From INR250, Keeps at Underperform MT
Laurus Labs Limited Announces Resignation of Chandrakanth Chereddi as Non-Executive Director CI
Transcript : Laurus Labs Limited, Q2 2024 Earnings Call, Oct 20, 2023
Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023 CI
Laurus Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Laurus Labs Limited agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million. CI
India's Divi's Labs Q1 profit slumps on drug pricing pressures RE
Laurus Labs' Consolidated Profit Tanks in Fiscal Q1; Shares Climb 4% MT
Chart Laurus Labs Limited
More charts
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
425.9 INR
Average target price
371.7 INR
Spread / Average Target
-12.72%
Consensus
  1. Stock Market
  2. Equities
  3. LAURUSLABS Stock
  4. LAURUSLABS Stock
  5. News Laurus Labs Limited
  6. Laurus Labs : Forms Partnership for Development of HIV Medication for Children